LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Longeveron Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.39+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $43.61M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$6.39 (−82.14%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Longeveron Inc. saw revenue fall 42.7% to $1.19M over the twelve months to Jun 30, 2026. Free cash flow was -$20.53M.
Revenue
$1.19M
-42.7% vs. a year earlier
Operating income
-$23.66M
TTM Q2 2026
Free cash flow
-$20.53M
TTM Q2 2026
EPS, diluted
-$0.77
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $43.61M
- P/E ratio
- –
- Price to sales
- 36.74
- Price to book
- 4.19
- Dividend yield
- –
- Free cash flow yield
- -47.08%
Fundamentals
- Revenue
- $1.19M
- Net income
- -$23.47M
- EPS, diluted
- -$0.77
- Free cash flow
- -$20.53M
- Book value per share
- $0.33
- Diluted shares
- 31M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$1.19M-42.7% YoY
Gross profit
$828.00K-49.3% YoY
Operating income
-$23.66M
Net income
-$23.47M
EPS, diluted
-$0.77
Free cash flow
-$20.53M
Reported periodTrailing twelve months